The efficacy of corticosteroid therapy in inflammatory bowel disease: Analysis of a 5-year UK inception cohort

Alimentary Pharmacology and Therapeutics

Volumn 24, Issue 2, 2006, Pages 319-330

  Ho, G T ^a,b   Chiam, P ^a   Drummond, H ^a   Loane, J ^a   Arnott, I D R ^a   Satsangi, J ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BUDESONIDE; CORTICOSTEROID; MESALAZINE; METHYLPREDNISOLONE; PREDNISOLONE;

ADULT; ARTICLE; CORTICOSTEROID THERAPY; CROHN DISEASE; DRUG EFFICACY; ENTERITIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; RISK FACTOR; TREATMENT FAILURE; TREATMENT OUTCOME; ULCERATIVE COLITIS; UNITED KINGDOM;

ADRENAL CORTEX HORMONES; ADULT; COHORT STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; DRUG RESISTANCE; FEMALE; HUMANS; MALE; REGRESSION ANALYSIS; RISK FACTORS; TREATMENT OUTCOME;

EID: 33745641871     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.02974.x     Document Type: Article

References (41)

1. Truelove SC, Witts LJ. Cortisone in ulcerative colitis: final report on a therapeutic trial. BMJ 1955; 4947: 1041-8.
2. Barnes PJ. Corticosteroid resistance in airway disease. Proc Am Thorac Soc 2004; 1: 264-8.
3. Chikanza IC, Kozaci DL. Corticosteroid resistance in rheumatoid arthritis: molecular and cellular perspectives. Rheumatology (Oxford) 2004; 43: 1337-45.
4. Carmichael J, Paterson C, Diaz P, Crompton GK, Kay AB, Grant W. Corticosteroid resistance in chronic asthma. BMJ 1981; 282: 1419-22.
5. Seki M, Ushiyama C, Seta N, et al. Apoptosis of lymphocytes induced by glucocorticoids and relationship to therapeutic efficacy in patients with systemic lupus erythematosus. Arthritis Rheum 1998; 41: 823-30.
6. van Schaardenburg D, Valkema R, Djikmans BA, et al. Prednisone treatment of elderly-onset rheumatoid arthritis. Disease activity and bone mass in comparison with chloroquine treatment. Arthritis Rheum 1995; 38: 823-30.
7. Farrell RJ, Kelleher D. Glucocorticoid resistance in inflammatory bowel disease. J Endocrinol 2003; 178: 339-46.
8. Laine L, Hanauer SB. Considerations in the management of steroid-dependent Crohn's disease. Gastroenterology 2003; 125: 906-10.
9. Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev 2000; 2: CD000067.
10. Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev 2000; 2: CD000545.
11. Jewell DP, Truelove SC. Azathioprine in ulcerative colitis: final report on controlled therapeutic trial. Br Med J 1974; 4: 627-30.
12. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002; 50: 485-9.
13. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 1995; 332: 292-7.
14. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 2000; 342: 1627-32.
15. Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi PG. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006; 55: 47-53.
16. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350: 876-85.
17. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9.
18. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76.
19. Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005; 128: 1805-11.
20. Gonzalez-Huix F, de Leon R, Fernandez-Banares F, et al. Polymeric enteral diets as primary treatment of active Crohn's disease: a prospective steroid controlled trial. Gut 1993; 34: 778-82.
21. Heuschkel RB. Enteral nutrition in children with Crohn's disease. J Pediatr Gastroenterol Nutr 2000; 31: 575.
22. Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for inducing remission of Crohn's disease. Cochrane Database Syst Rev 2001; 3: CD000542.
23. Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994; 35: 360-2.
24. Faubion WAJ, Loftus EVJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001; 121: 255-60.
25. Gasche C, Scholmerich J, Brynskov J, et al. A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 2000; 6: 8-15.
26. Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci (Lond) 1998; 94: 557-72.
27. Hyams JS, Markowitz JS, Griffiths A, et al. The natural therapy of corticosteroid therapy for ulcerative colitis in children. Gastroenterology 2005; M1157.
28. Jarnerot G, Rolny P, Sandberg-Gertzen H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology 1985; 89: 1005-13.
29. Hanauer SB. Top-down versus step-up approaches to chronic inflammatory bowel disease: presumed innocent or presumed guilty. Nat Clin Pract Gastroenterol Hepatol 2005; 2: 493.
30. Hommes DW, D'Haens G, Baert F, et al. Management of recent onset Crohn's disease-a controlled randomized trial comparing step-up and top-down therapy. Gastroenterology 2005 (abstract).
31. Reinisch W, Gasche C, Wyatt J, et al. Steroid dependency in Crohn's disease. Lancet 1995; 345: 859.
32. Ho GT, Mowat C, Goddard CJ, et al. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment Pharmacol Ther 2004; 19: 1079-87.
33. Farrell RJ, Murphy A, Long A, et al. High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterology 2000; 118: 279-88.
34. Honda M, Orii F, Ayabe T, et al. Expression of glucocorticoid receptor beta in lymphocytes of patients with glucocorticoid-resistant ulcerative colitis. Gastroenterology 2000; 118: 859-66.
35. Hearing SD, Norman M, Probert CS, Haslam N, Dayan CM. Predicting therapeutic outcome in severe ulcerative colitis by measuring in vitro steroid sensitivity of proliferating peripheral blood lymphocytes. Gut 1999; 45: 382-8.
36. Ho GT, Nimmo ER, Tenesa A, et al. Allelic variations of the multidrug resistance gene determine susceptibility and disease behavior in ulcerative colitis. Gastroenterology 2005; 128: 288-96.
37. Potocnik U, Ferkolj I, Glavac D, Dean M. Polymorphisms in multidrug resistance 1 (MDR1) gene are associated with refractory Crohn disease and ulcerative colitis. Genes Immun 2004; 5: 530-9.
38. Bouma G, Crusius JB, Garcia-Gonzalez MA, et al. Genetic markers in clinically well defined patients with ulcerative colitis (UC). Clin Exp Immunol 1999; 115: 294-300.
39. Roussomoustakaki M, Satsangi J, Welsh K, et al. Genetic markers may predict disease behavior in patients with ulcerative colitis. Gastroenterology 1997; 112: 1845-53.
40. Duerr RH, Chesny IJ. Associations between HLA-DR alleles and subsets of ulcerative colitis defined by extent of colitis. Gastroenterology 1997; A113.
41. Rhen T, Cidlowski JA. Anti-inflammatory action of glucocorticoids - new mechanisms for old drugs. N Engl J Med 2005; 353: 1711-23.